SCHEMBL6897965

SCHEMBL6897965

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSCCc2ccccc2)[C@@H](O)[C@H]1O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 6/20 0.76
DNMT3B Q9UBC3 3/20 0.76
PNMT P11086 2/20 0.76
DNMT1 P26358 2/20 0.76
CARM1 Q86X55 4/20 0.74
PRMT7 Q9NVM4 2/20 0.74
EHMT2 Q96KQ7 2/20 0.70
TRDMT1 O14717 1/20 0.70
PRMT5 O14744 1/20 0.70
SUV39H1 O43463 1/20 0.70
PRMT3 O60678 1/20 0.70
INMT O95050 1/20 0.70
NSD2 O96028 1/20 0.70
NNMT P40261 1/20 0.70
HNMT P50135 1/20 0.70
WDR5 P61964 1/20 0.70
KMT2A Q03164 1/20 0.70
SETDB1 Q15047 1/20 0.70
RBBP5 Q15291 1/20 0.70
EZH2 Q15910 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17551942 0.91 GNMT (0.80) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL6901855 0.91 GNMT (0.80) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL19434095 0.91 GNMT (0.80) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL9550942 0.91 GNMT (0.80) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL6907677 0.89 DOT1L (0.71) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL16486809 0.88 ADORA1 (0.69) DOT1LNNMTKMT2AEHMT1NADK
SCHEMBL14174635 0.87 DOT1L (1.00) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL16272276 0.87 DOT1L (1.00) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL1490901 0.87 DOT1L (0.84) DOT1LDNMT3BPNMTDNMT1CARM1
SCHEMBL8572440 0.87 DOT1L (1.00) DOT1LDNMT3BPNMTDNMT1CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482977-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed
WO-2003074083-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP DOT1L 1250/4885DNMT3B 408/4885PNMT 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.